Clinical trial · Observational
Neoadjuvant Immunochemotherapy for Lung Cancer
Retrospective Research on Lung Cancer Patients Receiving Neoadjuvant Immunochemotherapy From Zhongshan Hospital Fudan University.
NCT06023797CI-TRIAL-00069309completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
We retrospectively analyzed lung cancer patients who had NAICT and surgery in the Department of Thoracic Surgery, Zhongshan Hospital. NAICT was defined as chemotherapy that included at one application of PD-1 inhibitor.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Neoadjuvant immunochemotherapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- MAICT
- description
- chemotherapy that included at one application of PD-1 inhibitor
- interventionNames
- Drug: Neoadjuvant immunochemotherapy
Primary outcomes (2)
- measure
- Progression-free survival (PFS)
- timeFrame
- 2017-2023
- description
- Progression-free defined as status of recurrence of lung cancer
- measure
- Overall survival (OS)
- timeFrame
- 2017-2023
- description
- Overall defined as the living status, alive or dead
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Lung surgery was performed in the Department of Thoracic Surgery at Zhongshan Hospital; 2. At least one cycle of neoadjuvant treatment containing the immune drug PD-1 immunosuppressant was performed before surgery; 3. Malignancy was present and confirmed in the pathology before treatment and after surgery; 4. The lung lesion was the primary lesion. Exclusion Criteria: 1. No lung surgery was performed until 2022.11; 2. No preoperative neoadjuvant therapy was performed or recorded; 3. Neoadjuvant therapy did not include immune drugs; 4. Previous history of malignancy (including surgery and adjuvant therapy); 5. Previous use of system-related immune medicines, such as immunosuppressants and monoclonal antibodies; and 6. Other conditions inappropriate for enrollment by the investigator.
References
Publications (0)
Data not yet available
No reference posted for this study.